scholarly journals IgG seroprevalence of COVID‐19 among people living with HIV or at high risk of HIV in south‐west Germany: A seroprevalence study

HIV Medicine ◽  
2021 ◽  
Author(s):  
Dominic Kaddu‐Mulindwa ◽  
Lukas Keuser ◽  
Vadim Lesan ◽  
Jürgen Rissland ◽  
Sigrun Smola ◽  
...  
Keyword(s):  
High Risk ◽  
West Germany ◽  
People Living With Hiv ◽  
Seroprevalence Study ◽  
South West ◽  
Living With Hiv

Urgent need to address the slow scale-up of TB preventive treatment in the WHO South-East Asia Region

2021 ◽  
Vol 25 (5) ◽  
pp. 382-387
Author(s):  
S. Satyanarayana ◽  
V. Bhatia ◽  
P. P. Mandal ◽  
A. Kanchar ◽  
D. Falzon ◽  
...  
Keyword(s):  
High Risk ◽  
East Asia ◽  
Scale Up ◽  
Preventive Treatment ◽  
People Living With Hiv ◽  
South East Asia ◽  
High Level ◽  
Almost All ◽  
Living With Hiv ◽  
East Asia Region

In September 2018, all countries made a commitment at the first ever United Nations High‐Level Meeting (UNHLM) on TB, to provide TB preventive treatment (TPT) to at least 30 million people at high‐risk of TB disease between 2018 and 2022. In the WHO South‐East Asia Region (SEA Region), which accounts for 44% of the global TB burden, only 1.2 million high‐risk individuals (household contacts and people living with HIV) were provided TPT (11% of the 10.8 million regional UNHLM TPT target) in 2018 and 2019. By 2020, almost all 11 countries of the SEA Region had revised their policies on TPT target groups and criteria to assess TPT eligibility, and had adopted at least one shorter TPT regimen recommended in the latest WHO TPT guidelines. The major challenges for TPT scale‐up in the SEA Region are resource shortages, knowledge and service delivery/uptake gaps among providers and service recipients, and the lack of adequate quantities of rifapentine for use in shorter TPT regimens. There are several regional opportunities to address these gaps and countries of the SEA Region must make use of these opportunities to scale up TPT services rapidly to reduce the TB burden in the SEA Region.

scholarly journals The Dark Side of Female HIV Patient Care: Sexual and Reproductive Health Risks in Pre- and Post-Clinical Treatments

2018 ◽  
Vol 7 (11) ◽  
pp. 402 ◽  
Author(s):  
Thu Khuat ◽  
Thu Do ◽  
Van Nguyen ◽  
Xuan Vu ◽  
Phuong Nguyen ◽  
...  
Keyword(s):  
Health Care ◽  
High Risk ◽  
Reproductive Health ◽  
Sexual And Reproductive Health ◽  
Hiv Care ◽  
High Risk Population ◽  
People Living With Hiv ◽  
Women Living With Hiv ◽  
Women And Girls ◽  
Living With Hiv

This study examines the pre- and post-clinical issues in human immunodeficiency virus (HIV) care and treatment for women and girls of high-risk population groups—namely sex workers, injecting drug users, women living with HIV, primary sexual partners of people living with HIV, adolescent girls who are children of these groups, and migrant young girls and women—in five provinces and cities in Vietnam. Through a sample of 241 surveyed participants and 48 respondents for in-depth interviews and 32 respondents in the focus group discussions, the study identifies multiple barriers that keep these groups from receiving the proper health care that is well within their human rights. Most respondents rated HIV testing as easily accessible, yet only 18.9% of the surveyed women living with HIV disclosed their infection status, while 37.8% gave no information at the most recent prenatal care visit. The level of knowledge and proper practices of sexual and reproductive health (SRH) care also remains limited. Meanwhile, modern birth control methods have yet to be widely adopted among these populations: only 30.7% of respondents reported using condoms when having sex with their husband. This increases the risks of unwanted pregnancy and abortion, as well as vulnerability to sexually transmitted infections (STIs) and HIV transmission. On the other hand, HIV-related stigma and discrimination at health care settings are still pervasive, which create significant barriers for patients to access proper care services. Based on these results, six recommendations to improve SRH status of women and girls of populations at high risk are put forward.

scholarly journals Systems analysis of gut microbiome influence on metabolic disease in HIV and high-risk populations

2021 ◽  
Author(s):  
Abigail J.S. Armstrong ◽  
Kevin Quinn ◽  
Jennifer Fouquier ◽  
Sam X. Li ◽  
Jennifer M. Schneider ◽  
...  
Keyword(s):  
Metabolic Disease ◽  
High Risk ◽  
Bacterial Translocation ◽  
Gut Microbiome ◽  
Metabolic Health ◽  
Hiv Positive ◽  
People Living With Hiv ◽  
Gut Microbes ◽  
Microbiome Composition ◽  
Living With Hiv

AbstractPoor metabolic health, characterized by insulin resistance and dyslipidemia, is higher in people living with HIV and has been linked with inflammation, anti-retroviral therapy (ART) drugs, and ART-associated lipodystrophy (LD). Metabolic disease is associated with gut microbiome composition outside the context of HIV but has not been deeply explored in HIV infection nor in high-risk men who have sex with men (HR-MSM), who have a highly altered gut microbiome composition. Furthermore, the contribution of increased bacterial translocation and associated systemic inflammation that has been described in HIV-positive and HR-MSM individuals has not been explored. We used a multi-omic approach to explore relationships between impaired metabolic health, defined using fasting blood markers, gut microbes, immune phenotypes and diet. Our cohort included ART-treated HIV positive MSM with and without LD, untreated HIV positive MSM, and HR-MSM. For HIV positive MSM on ART, we further explored associations with the plasma metabolome. We found that elevated plasma lipopolysaccharide binding protein (LBP) was the most important predictor of impaired metabolic health and network analysis showed that LBP formed a hub joining correlated microbial and immune predictors of metabolic disease. Taken together, our results suggest the role of inflammatory processes linked with bacterial translocation and interaction with the gut microbiome in metabolic disease among HIV positive and negative MSM.Importance StatementThe gut microbiome in people living with HIV (PLWH) is of interest as chronic infection often results in long term comorbidities. Metabolic disease is prevalent in PLWH even in well-controlled infection and has been linked with the gut microbiome in previous studies, but little attention has been given to PLWH. Furthermore, integrated analyses that consider gut microbiome together with diet, systemic immune activation, metabolites, and demographics have been lacking. In a systems-level analysis of predictors of metabolic disease in PLWH and men who are at high risk of acquiring HIV, we found that increased LBP, an inflammatory marker indicative of compromised intestinal barrier function, was associated with worse metabolic health. We also found impaired metabolic health associated with specific dietary components, gut microbes, and host and microbial metabolites. This work lays the framework for mechanistic studies aimed at targeting the microbiome to prevent or treat metabolic endotoxemia in HIV-infected individuals.

Sign in / Sign up

Export Citation Format

Share Document